German healthcare company Fresenius Medical Care has agreed to pay more than $231 million to resolve parallel investigations by the Department of Justice and the Securities and Exchange Commission for violations of the Foreign Corrupt Practices Act.
In a Feb. 20 Form 20-F filing, Fresenius previously disclosed that, beginning in 2012, it received certain communications alleging conduct in countries outside the United States concerning potential violations of the FCPA and other anti-bribery laws. “The company’s supervisory board, through its audit and corporate governance committee, conducted investigations with the assistance of independent counsel,” Fresenius said in that financial filing.
